Drugs / RAY1225
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07460284 | Mar → Oct 2026 expected | — | Guangdong Raynovent Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07362030 | Apr → Dec 2025 overdue | obesity disorder | Guangdong Raynovent Biotech Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06613763 | Sep 2024 → Jan 2025 | impaired renal function disease | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06577415 | Aug 2024 → Oct 2025 overdue | — | Guangdong Raynovent Biotech Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06577428 | Jul → Sep 2024 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05835752 | May 2023 → Mar 2024 | obesity disorder | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06254274 | Feb 2024 → Dec 2025 overdue | type 2 diabetes mellitus | Guangdong Raynovent Biotech Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06254261 | Feb 2024 → Dec 2025 overdue | obesity disorder | Guangdong Raynovent Biotech Co., Ltd | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07139548 | Aug 2025 → Dec 2026 expected | type 2 diabetes mellitus | Guangdong Raynovent Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07139535 | Aug 2025 → Dec 2026 expected | type 2 diabetes mellitus | Guangdong Raynovent Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06893016 | Jun 2025 → Jun 2026 overdue | obesity disorder | Guangdong Raynovent Biotech Co., Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-10-09 | Guangdong Raynovent Biotech Co., Ltd | Results EASD 2026 口头报告 | 众生睿创RAY1225降糖II期研究闪耀亮相：24周HbA1c降幅最高2.76%，15mg组HbA1c<7%达标率100% raynovent.com ↗
数据显示，RAY1225 15mg组在24周治疗期内实现糖化血红蛋白（HbA1c）平均降幅达2.76%，HbA1c<7%达标率高达100%，且HbA1c降至5.34%接近正常水平。 |
| 2026-06-08 | Guangdong Raynovent Biotech Co., Ltd | Results 2026 ADA口头报告 | 众生睿创RAY1225注射液Ⅱ期研究闪耀亮相：24周减重最高达21.2% raynovent.com ↗
研究结果显示，给药后24周，RAY1225各剂量组均展现出显著且呈剂量依赖性的减重效果，9 mg组较基线下降14.75%，18 mg组下降21.18%。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-10-09 | Guangdong Raynovent Biotech Co., Ltd | EASD 2026 口头报告 | 众生睿创RAY1225降糖II期研究闪耀亮相：24周HbA1c降幅最高2.76%，15mg组HbA1c<7%达标率100% raynovent.com ↗ |
| 2026-06-08 | Guangdong Raynovent Biotech Co., Ltd | 2026 ADA口头报告 | 众生睿创RAY1225注射液Ⅱ期研究闪耀亮相：24周减重最高达21.2% raynovent.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAY1225 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06254274 ↗ |
| Route | Subcutaneous | “Escalating doses of RAY1225 administered subcutaneously (SC) once in healthy participants.” NCT05835752 ↗ |